Researchers used computer modeling to design stapled peptide inhibitors that target Bcr-Abl's assembly mechanism — a novel approach to treating chronic myeloid leukemia that bypasses current drug resistance problems.
New target, new approachInstead of targeting Bcr-Abl's kinase domain like current drugs, these stapled peptides block the coiled-coil assembly domain — potentially working against drug-resistant leukemia
What the researchers found
The researchers used computational modeling to design next-generation stapled peptide inhibitors targeting Bcr-Abl, the fusion protein that causes chronic myeloid leukemia (CML). By incorporating hydrocarbon staples — chemical cross-links that lock the peptide into a stable helical shape — they aimed to overcome the conformational instability and protease vulnerability of their previous 81-amino-acid inhibitor construct.
The team modeled both single and double staple configurations across full-length and truncated peptide versions, with and without a cell-penetrating peptide (CPP) component. They identified lead candidates predicted to maintain strong binding to Bcr-Abl's coiled-coil oligomerization domain while being more stable and resistant to degradation than the unstapled version. These candidates are proposed for experimental validation.
Why it matters
Current CML treatments (tyrosine kinase inhibitors like imatinib) target Bcr-Abl's kinase domain, but resistance mutations remain a major problem. This peptide approach attacks a completely different target — the coiled-coil domain that Bcr-Abl needs to assemble and activate. If stapled peptide inhibitors can block this assembly, they could work even against kinase-inhibitor-resistant leukemia. This represents a fundamentally different therapeutic strategy for a common blood cancer.
The numbers in context
81-amino-acid parent construct · Hydrocarbon staples at i, i+7 positions · 6 system variants modeled (full-length/truncated × no CPP/cyclic CPP/linear CPP) · Single and double staple candidates screened · Targets Bcr-CC oligomerization domain
How the study worked
The researchers used computational molecular dynamics simulations to model and screen stapled peptide candidates. They evaluated binding energetics (how strongly the peptide binds its target), conformational stability (how well the peptide maintains its active shape), and the impact of different staple configurations. The modeling library included six system variants combining full-length versus truncated peptides with different cell-penetrating peptide configurations.
Who was studied
Computational study (no biological samples)
What this study cannot tell us
This is entirely a computational study — no experimental synthesis or biological testing has been performed on the stapled candidates presented here. Computational predictions of binding affinity and stability don't always translate to actual biological activity. The bioRxiv preprint has not undergone peer review. Stapled peptides face general challenges with cellular uptake, tissue distribution, and manufacturing that aren't addressed by computational modeling alone.
How to read the evidence
This is a computational preprint study with no experimental validation data. While the modeling approach is rigorous and builds on prior published work, the lead candidates have not been synthesized or tested in biological systems. The evidence is preliminary and hypothesis-generating.
When this study was published
Posted as a bioRxiv preprint in 2023, this represents early-stage research. Experimental validation results may have been published since. The computational approach reflects current state-of-the-art methods in peptide drug design.
The bigger picture
Stapled peptides are a rapidly advancing class of therapeutics that bridge the gap between small-molecule drugs and large biologics. They can target protein-protein interactions that small molecules can't reach. This work applies stapled peptide technology to one of oncology's most validated targets (Bcr-Abl) via a novel mechanism (blocking assembly rather than enzyme activity), potentially offering a new treatment option for drug-resistant leukemia.
Questions still open
- Will the computationally predicted stapled peptide candidates show the expected binding and stability when synthesized and tested in the lab?
- Can stapled peptides achieve sufficient cellular uptake in leukemia cells to block Bcr-Abl assembly at therapeutic concentrations?
- Would this approach work against the most problematic Bcr-Abl resistance mutations like T315I?
Common questions
What are stapled peptides and why are they useful?
How would this peptide approach differ from current leukemia drugs?
Read the original research
Computational Modeling of Stapled Coiled-Coil Inhibitors Against Bcr-Abl: Toward a Treatment Strategy for CML.
bioRxiv : the preprint server for biology
Citation
Lima, Maria Carolina P; Hornsby, Braxten D; Lim, Carol S; Cheatham, Thomas E. (2023). Computational Modeling of Stapled Coiled-Coil Inhibitors Against Bcr-Abl: Toward a Treatment Strategy for CML.. bioRxiv : the preprint server for biology. https://doi.org/10.1101/2023.11.15.566894